within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX26_Amenamevir;

model Amenamevir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.87,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.139,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013500000000000002,
    Tlag = 10.200000000000001,
    Vdp = 0.061,
    k12 = 5.194444444444445e-06,
    k21 = 5.194444444444445e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Amenamevir</td></tr><tr><td>ATC code:</td><td>J05AX26</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>139</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Amenamevir is an orally active helicase-primase inhibitor used for the treatment of herpes zoster (shingles) in adults. It is approved and marketed in Japan for this indication. Amenamevir inhibits the helicase-primase complex essential for herpesvirus DNA replication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese volunteers receiving single oral doses of amenamevir.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AX26 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Amenamevir;
